

References – Nevanac

1. Canadian Ophthalmological Society Cataract Surgery Clinical Practice Guideline Expert Committee. Canadian Ophthalmological Society evidence-based clinical practice guidelines for cataract surgery in the adult eye. *Can J Ophthalmol*. 2008 Oct;43 Suppl 1:S7-57. Available: <http://pubs.nrc-cnrc.gc.ca/cjo/cjo43/i08-133.pdf>
2. Bollinger KE, Langston RH. What can patients expect from cataract surgery? *Cleve Clin J Med*. 2008 Mar;75(3):193-6, 199-200. Available: <http://www.ccjm.org/content/75/3/193.full.pdf+html>
3. Toward Optimized Practice. Guideline for Surgical & Non-Surgical Management of Cataract in the Otherwise Healthy Adult Eye; 2008 [date of last review]. Available: http://www.topalbertadoctors.org/PDF/complete%20set/Cataracts/cataract_guideline.pdf
4. DeCroos FC, Afshari NA. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. *Curr Opin Ophthalmol*. 2008 Jan;19(1):22-6.
5. European Medicines Agency. Scientific discussion (Nevanac); 2007. Available: <http://www.emea.europa.eu/humandocs/PDFs/EPAR/nevanac/H-818-en6.pdf>
6. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. *J Cataract Refract Surg*. 2007 Jan;33(1):53-8.
7. Maxwell WA, Reiser HJ, Stewart RH, Cavanagh HD, Walters TR, Sager DP, Meuse PA. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. *J Ocul Pharmacol Ther*. 2008 Dec;24(6):593-9.
8. Duong HV, Westfield KC, Chalkley TH. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. *J Cataract Refract Surg*. 2007 Nov;33(11):1925-9.
9. Mathys KC, Cohen KL. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. *Eye*. 2009 Feb 20.
10. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. *J Cataract Refract Surg*. 2007 Sep;33(9):1546-9.
11. McCulley JP. Ketorolac versus nepafenac in cataract surgery. *J Cataract Refract Surg*. 2008 Mar;34(3):345-6.
12. Guidelines & Protocols Advisory Committee. Cataract – Treatment of Adults; 2007 [date of revision]. Available: <http://www.bcguidelines.ca/gpac/pdf/cataract.pdf>
13. Cataract in the adult eye. Preferred practice pattern. In: American Academy of Ophthalmology (AAO). San Francisco (CA): American

Academy of Ophthalmology (AAO); 2006. Available:
<http://one.aao.org/asset.axd?id=821cecfb-85c5-400d-a65f-7a9a727bc163>

14. American Optometric Association. Care of the adult patient with cataract. 2nd ed. St. Louis (MO): American Optometric Association; 1996. 84 p. (Optometric clinical practice guideline; no. 16). Available:
<http://one.aao.org/asset.axd?id=821cecfb-85c5-400d-a65f-7a9a727bc163>
15. Lindstrom R. The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. *International Ophthalmology Clinics*. 2006;46(4):7-11.
16. Bartlett JD, Fiscella RG, Bennett E, Jaanus SD, Rowsey JJ, Zimmerman TJ, editors. *Ophthalmic Drug Facts, 2001*. St. Louis: Facts and Comparisons; 2001.
17. American Society of Health-System Pharmacists. AHFS Drug Information® (2009). In: STAT!Ref Online Electronic Medical Library [database on the Internet; cited March 13, 2009]. Bethesda: American Society of Health-System Pharmacists; 2009.
18. Corticosteroids: Eye Ear Nose. e-CPS 2009.
19. George SP. Cataract Surgery Postoperative Care. In: Gray J, ed. *Therapeutic Choices, 5th edition*, Ottawa, ON: Canadian Pharmacists Association, 2007: 273-84.